ETFIQ
RankingsCompareHoldingsResearch
My portfolioWeekly note

SBIO · ALPS Medical Breakthroughs ETF

Equity fundTracks an index0.50% fee$162mSince Dec 31, 2014SEC filings ↗
Share on XDownload as PDFCompareAdd to portfolioAlerts

SBIO tracks an index and returned +43.9% over the past year.

+43.9%
Total return, 1 year
0.50%
Expense ratio
82
Holdings
−20.7%
Below its high
WindowTotal returnS&P 500Gap to S&P 500Gap to Nasdaq-100
3M Jul 2 – Oct 2, 2026−13.5%+3.6%−17.1 pts−18.8 pts
6M Apr 2 – Oct 2, 2026+5.0%+17.9%−13.0 pts−23.4 pts
1Y Oct 2, 2025 – Oct 2, 2026+43.9%+16.2%+27.7 pts+19.6 pts
3Y Oct 3, 2023 – Oct 2, 2026+122.4%+89.3%+33.1 pts+7.6 pts
Since listing Dec 31, 2014 – Oct 2, 2026+145.7%+354.8%−209.1 pts−546.6 pts

SBIO over each window to Oct 2, 2026. Every figure is an ETFIQ calculation. Source: ETFIQ.

SBIO top ten by weight, 34.8% of its 82 equity positions, from the holdings filed for May 31, 2026. An index fund holds what the index holds, so this is the index. Source: the fund’s SEC filing.

Alkermes Plc 4.48%
Kymera Therapeutics Inc 4.23%
Celcuity Inc 3.92%
Mirum Pharmaceuticals Inc 3.90%
Spyre Therapeutics Inc 3.68%
Cg Oncology Inc 3.35%
Apogee Therapeutics Inc 2.93%
Xenon Pharmaceuticals Inc 2.90%
Travere Therapeutics Inc 2.77%
Dianthus Therapeutics Inc 2.63%
Fund filings on SEC EDGAR ↗
Head to head
Funds near this one
ACWIACWXAIRRAORAVDVAVEM

In plain words

SBIO tracks an index. Over the year to Oct 2, 2026 it returned +43.9% with distributions reinvested, against +16.2% for the S&P 500 and +24.3% for the Nasdaq-100. The prospectus expense ratio is 0.50% a year. By its holdings filed for May 31, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 82 positions, with the top ten at 34.8%. It sat 20.7% below its high of Aug 19, 2026 on Oct 2, 2026.
What it tracksnot read by ETFIQ
Fund typeEquity fund
Category (ETFIQ)Stocks · Health care
Expense ratio (485BPOS XBRL, Mar 30, 2026)0.50%
Price$56.15
Listed sinceDec 31, 2014
Net assets (SEC filing, whole fund, as filed for May 31, 2026)$162m
Below its high (ETFIQ)−20.7%
Holdings82
Top ten weight34.8%
Holdings as of (SEC N-PORT)May 31, 2026
Already in the S&P 500, by weight (ETFIQ)0.0%
Active share vs the S&P 500 (ETFIQ)100.0%
Already in the Nasdaq-100, by weight (ETFIQ)0.0%
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

Questions people ask about SBIO

How has SBIO performed?
Over the year to Oct 2, 2026, SBIO returned +43.9% with distributions reinvested, against +16.2% for the S&P 500. Over three years the figure is +122.4%.
What does SBIO cost?
The prospectus expense ratio is 0.50% a year.
What does SBIO hold?
82 positions as filed for May 31, 2026, with the top ten at 34.8% of the fund. 0% of its weight is in stocks the S&P 500 also holds.
How far is SBIO below its high?
20.7% below its high of Aug 19, 2026, measured on the reinvested series to Oct 2, 2026.
Sources and dates
Prices, SBIO and S&P 500Tiingo end-of-day · Oct 2, 2026
Fee, 0.50%Prospectus filing with the expense ratio (SEC) ↗
Net assets, $162mSEC filing, whole fund · May 31, 2026
HoldingsHoldings filing (SEC Form N-PORT) · May 31, 2026 ↗
IssuerALPS website ↗
All fund filingsFund filings on SEC EDGAR ↗
SourceALPS’s own site ↗

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

ETFIQ covers core, leveraged and inverse, buffer, thematic, option-income, alternatives and spot crypto ETFs. This fund is here because the other funds here are measured against it and portfolios hold it. ETFIQ is an independent publisher and makes no recommendations. Standards and sources

How these figures are computed →Standards and sources →Open data →
Cite this page

ETFIQ, SBIO, core fund, data as of Oct 2, 2026. https://etfiq.com/funds/sbio

Free to use with attribution; the underlying files are at Open data.

ALPS: every fund ETFIQ covers→